Other

PT-141

A cyclic heptapeptide derived from Melanotan II, researched for selective melanocortin-4 receptor activity in sexual-response studies.

Also known as: Bremelanotide

Quick facts

Molecular weight

1,025 Da

Half-life

2 h

Frequency

every other-day

Admins / wk

3.5

Routes

SubQ

Typical dose

500 mcg–2.00 mg

Mechanism & positioning

A cyclic heptapeptide derived from Melanotan II, researched for selective melanocortin-4 receptor activity in sexual-response studies.

Researched for: MC4 receptor agonism, sexual-response pathways.

Reconstitution defaults

Default vial

10 mg

BAC water

2 mL

Concentration

5000 mcg/mL

Doses per vial

~20

Calculate with this peptide

Documented pairwise interactions

warning
PT-141 + Melanotan II
Both act on melanocortin receptors; overlapping mechanism increases probability of nausea and pressor effects.

References

Pfaus JG et al., J Sex Med, 2007.

Related peptides in the Other class

Frequently asked questions about PT-141

What is the typical research dose range for PT-141?

PT-141 is most commonly investigated at 500 mcg–2.00 mg per administration, every other-day. These values reflect documented research-stage protocols and are not medical recommendations.

What is the half-life of PT-141?

PT-141 has an approximate plasma half-life of 2 hours. Practical steady state is reached after roughly five half-lives — about 0 days under continuous administration.

How is PT-141 administered in research protocols?

Published research uses subq administration. Typical reconstitution is 10 mg vial in 2 mL of bacteriostatic water, producing a concentration of 5000 mcg/mL.

What vial sizes are commonly available for PT-141?

Common stocked vial sizes are 10 mg. The 10 mg vial is the most-used default in published protocols.